Form 4: Iovance Biotherapeutics COO Igor Bilinsky Reports Stock Transactions
SEC Form 4 Filing
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On March 3, 2025, Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, had restricted stock units (RSUs) vest, resulting in the acquisition of 62,106 shares of common stock.
- The company withheld 33,302 shares to satisfy tax obligations at a price of $4.04 per share.
- Following these transactions, Bilinsky directly owns 87,578 shares of common stock.
- He also holds 70,317 RSUs granted on March 1, 2024, and 14,065 RSUs granted on March 2, 2023, which will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency into insider transactions.
Positives
- The vesting of RSUs indicates a form of compensation and alignment of the COO's interests with the company's performance.
Future Outlook
The remaining RSUs will vest in equal quarterly installments, suggesting continued equity-based compensation for the reporting person.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for investor confidence in the biotechnology industry.
Comparison to Industry Standards
- Equity compensation, including RSUs, is a common practice in the biotechnology industry to attract and retain talent.
- Companies like Gilead Sciences, Amgen, and Biogen also use RSUs as part of their executive compensation packages.
- The vesting schedules and amounts vary based on individual performance and company policies.
Stakeholder Impact
- Shareholders gain insight into executive compensation and ownership.
- Employees may be impacted by the overall financial health of the company, which is indirectly reflected in executive compensation.
Key Dates
| Date | Description |
|---|---|
| 03/02/2023 | Date of grant for some of the restricted stock units held by Igor Bilinsky. |
| 03/01/2024 | Date of grant for some of the restricted stock units held by Igor Bilinsky. |
| 03/03/2025 | Date of transaction: vesting of RSUs and withholding of shares for taxes. |
| 03/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.